Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Lung Cancer
 More »

  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    Boehringer Ingelheim will be presenting data from its Phase III studies on afatinib and nintedanib in two populations of patients with advanced non-small-cell-lung cancer (NSCLC) ...
    5-16-2013
  • Moving Genomics Closer to the Clinic
    ... One test, developed by Abbott Laboratories in collaboration with Pfizer, identifies patients with a rare form of lung cancer linked to the anaplastic lymphoma kinase (ALK) gene. ...
    5-15-2013
  • FDA Approves Roche EGFR Mutation CDx for NSCLC
    it also approved for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients whose tumors show EFGR exon 19 deletions or exon 21 substitution mutations. ...
    5-15-2013
  • Softening the Blow from FOLFOX Treatment
    500,000 (about $79,000) Vinnova grant awarded last year, PledPharma has performed some preclinical studies on PledOx and chemotherapies involved with non-small-cell lung cancer. ...
    5-15-2013
  • Sorrento, Igdrasol Secure Exclusive E.U. Distribution Rights...
    Cynviloq is already approved and marketed in several countries for indications including metastatic breast cancer, non-small-cell lung cancer, and ovarian cancer. Sorrento and ...
    5-14-2013
  • Lilly Halts Development of Lymphoma Drug After Phase III Failure
    ... Those two Phase III molecules are necitumumab, indicated for squamous non-small cell lung cancer; and ramucirumab for breast cancer, colorectal cancer, and gastric cancer. Lilly ...
    5-10-2013
  • Amgen Forms Joint Venture to Sell Vectibix in China
    Founded in 2003, Zhejiang launched Icotinib for non-small cell lung cancer (NSCLC) in China two years ago. Ownership of the new venture, to be named Amgen-Beta Pharmaceuticals, ...
    5-10-2013
  • Companion Diagnostics: 52 Pick-Up
    ... Gene via FISH in FFPE non-small cell lung cancer (NSCLC) tissue specimens to aid in identifying patients eligible for treatment with Xalkori (crizotinib). For prescription use ...
    5-9-2013
  • Cancer Diagnostics, Pushing the Boundaries
    ... in the OncoNetwork Consortium, evaluated a custom gene panel that targets hotspot mutations in 22 genes implicated in colorectal cancer and non-small-cell lung carcinoma. ...
    5-8-2013
  • Harnessing the Power of Kinase Inhibitors
    ... inhibitors in pancreatic and ovarian cancer cell lines, specifically by preventing ... The in vivo model induced inflammation in the mouse lung to mimic an asthmatic response. ...
    5-8-2013
  • The Tumor Microenvironment as a Drug Target, Part II
    ... The investigators reported that the miRNA pair inhibited lung metastasis by breast tumor ... of chemokine (C-C motif) ligand 2 (Ccl2) by cancer cells in an SDF-1α-dependent manner. ...
    5-7-2013
  • Two Proteins Found to Block Cancer Metastasis
    professor of cell and developmental biology in cardiothoracic surgery and director of the Neuberger Berman Foundation Lung Cancer Laboratory at Weill Cornell Medical College. ...
    5-1-2013
  • Exposing the Exposome
    ... These modifications were used to establish biomarkers with potential diagnostic relevance, which can predict which subset of smokers have or are at higher risk for lung cancer. "We ...
    5-1-2013
  • The Tumor Microenvironment as a Drug Target: Chasing Slippery...
    They showed that genetic deletion and pharmacologic inhibition of FAP inhibited tumor growth in an endogenous mouse model of lung cancer driven by the K-rasG12D mutant. FAP ...
    5-1-2013
  • Detecting Acquired Drug Resistance in Cancer
    As an example, 70-80% of patients receiving cytotoxic therapy for lung cancer obtain little-to-no clinical benefit from their treatment. The marginal success rate achieved in many ...
    4-29-2013
  • More »

    Journal Articles

  • The Impact of Distant Metastases at Presentation on Prognosis...
    Iain J. Nixon, Monica M. Whitcher, Frank L. Palmer, R. Michael Tuttle, Ashok R. Shaha, Jatin P. Shah, Snehal G. Patel, Ian Ganly
    Thyroid
    and skin in one, and one patient had synchronous lung, bone, and intracerebral metastases. ... Twenty-nine patients (56%) died during follow-up, of whom 24 (46%) died of thyroid cancer. ...
  • Pneumocystis jiroveci Pneumonia in an Immunocompetent Patient
    Genaro Maggi, Emilio Maseda, Ana Gomez Rice, Fernando Gilsanz Rodriguez
    Surgical Infections
    risk of developing pneumonia, despite immunocompetence, such as smoking, COPD, a health personnel, lung cancer, interstitial lung diseases and exposure to corticosteroid therapy. ...
  • Two Patients with Highly Aggressive Macrofollicular Variant of...
    Monica G. Cardenas, Sudha Kini, Max Wisgerhof
    Thyroid
    was reviewed and reclassified as MFV-PTC. The patient developed new bone and lung metastases. Three treatments with 131I were not effective. He died of metastatic thyroid cancer. ...
  • Dual Localization Technique for Thoracoscopic Resection of Lung...
    Francois I. Luks, Abigail E. Martin, James Y. Chen, Christopher S. Muratore, William W. Mayo-Smith
    Journal of Laparoendoscopic& Advanced Surgical Techniquesand Part B, Videoscopy
    Dual Localization Technique for Thoracoscopic Resection of Lung Lesions in Children ... acceptance as a method of resecting pulmonary metastases in pediatric cancer patients. ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll